COGT News and Press, Cogent Biosciences Inc Com From 06/10/22

All patients treated with bezuclastinib achieved ≥ 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥ 50% bone marrow mast cell reduction&#...

CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it will host an investor webcast on Friday, June 10, 2022 a...

CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the Annual Meeting of Stockholders will take place virtuall...

CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Association...

Cogent Biosciences press release (NASDAQ:COGT): Q1 Net loss was $30.6 million. As of March 31, 2022, cash and cash equivalents were $191.0 million as compared to $219.7 million as of December 31, 2021. For further details see: Cogent Biosciences reports Q1 results

Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class small molecule kinase inhibitors for genetically defined oncology indications and ...

Cogent Biosciences (NASDAQ:COGT) on Friday filed for a $300M mixed shelf offering. The offering can include stock, preferred stock, debt securities, warrants and units. Proceeds will be used for development, regulatory and commercial preparation activities relating to bezuclastinib and other ...

CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the L...

Shares of Cogent Biosciences Inc. (NASDAQ:COGT) traded at a new 52-week high today of $13.82. Approximately 17.1 million shares have changed hands today, as compared to an average 30-day volume of 250,000 shares. Over the past year, Cogent Biosciences Inc. has traded in a range of $2.20 ...

New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors Building a pipeline of multiple small molecule inhibitors targeting genetically defined diseases, includi...